Cipla has announced that its manufacturing facility in Bommasandra, Bengaluru, has received a Voluntary Action Indicated (VAI) classification from the United States Food and Drug Administration (USFDA) following a recent inspection.

The USFDA conducted a current Good Manufacturing Practices (cGMP) inspection at Cipla's Bommasandra facility from May 26 to May 30. Following the inspection, the regulatory agency communicated its decision via email on August 4, classifying the facility as VAI.

The company disclosed this development to stock exchanges in compliance with SEBI regulations.

A VAI classification indicates that while the USFDA found objectionable conditions or practices during the inspection, the agency is not prepared to take or recommend any administrative or regulatory action. 

It allows the company to address the issues voluntarily while continuing operations at the facility.